Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

First Posted Date
2020-12-24
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
160
Registration Number
NCT04684368
Locations
🇺🇸

University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States

🇺🇸

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States

🇦🇺

Sydney Children's Hospital, Randwick, New South Wales, Australia

and more 151 locations

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Posted Date
2020-12-14
Last Posted Date
2024-08-26
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
41
Registration Number
NCT04665765
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

🇺🇸

City of Hope Medical Center, Duarte, California, United States

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

First Posted Date
2020-11-12
Last Posted Date
2024-05-23
Lead Sponsor
University of Birmingham
Target Recruit Count
1672
Registration Number
NCT04625907
Locations
🇬🇷

University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece

🇮🇱

Rambam Health Care Campus, Haifa, Israel

🇮🇱

Hadassah University Medical Centre, Jerusalem, Israel

and more 125 locations

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

First Posted Date
2020-07-17
Last Posted Date
2022-06-09
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
29
Registration Number
NCT04475016
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

First Posted Date
2020-04-22
Last Posted Date
2020-07-14
Lead Sponsor
Fudan University
Target Recruit Count
45
Registration Number
NCT04356872
Locations
🇨🇳

Fudan University, Cancer Hospital, Shanghai, Shanghai, China

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

First Posted Date
2020-03-26
Last Posted Date
2024-12-04
Lead Sponsor
Children's Oncology Group
Target Recruit Count
221
Registration Number
NCT04322318
Locations
🇺🇸

Tufts Children's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States

and more 193 locations

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

First Posted Date
2020-01-09
Last Posted Date
2024-05-16
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
800
Registration Number
NCT04221035
Locations
🇬🇷

University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece

🇬🇷

Children's General Hospital "AGHIA SOFIA", Athens, Greece

🇮🇹

instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

First Posted Date
2019-12-13
Last Posted Date
2024-10-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
20
Registration Number
NCT04199026
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

First Posted Date
2019-12-06
Last Posted Date
2022-09-19
Lead Sponsor
University of Miami
Target Recruit Count
2
Registration Number
NCT04189952
Locations
🇺🇸

University of Miami, Miami, Florida, United States

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

First Posted Date
2019-11-06
Last Posted Date
2024-07-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
81
Registration Number
NCT04154189
Locations
🇺🇸

Loma Linda University Medical Center, Loma Linda, California, United States

🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 81 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy